Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.37
- Piotroski Score 3.00
- Grade Overweight
- Symbol (SLRN)
- Company Acelyrin, Inc.
- Price $4.93
- Changes Percentage (1.02%)
- Change $0.05
- Day Low $4.89
- Day High $5.03
- Year High $10.71
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $9.50
- High Stock Price Target $13.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.43
- Trailing P/E Ratio -1.84
- Forward P/E Ratio -1.84
- P/E Growth -1.84
- Net Income $-381,641,000
Income Statement
Quarterly
Annual
Latest News of SLRN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now?
Acelyrin, Inc. (NASDAQ:SLRN) is a promising biopharmaceutical company specializing in autoimmune disease treatments. Despite setbacks, recent trial successes and strong financials position SLRN as one...
By Yahoo! Finance | 1 month ago -
Here's Why We're Watching Acelyrin's (NASDAQ:SLRN) Cash Burn Situation
Despite losses, shareholders can profit by investing in a good business at the right price. Acelyrin's cash burn rate and runway are examined, revealing potential concerns despite its solid cash reser...
By Yahoo! Finance | 2 months ago